SenzaGen’s Capital Raising

Baker McKenzie advised SenzaGen in connection with the transactions.

SenzaGen AB (SenzaGen) has raised approximately SEK 100 million (approx. US 10.68 million) through a private placement and a preferential rights issue of shares.

SenzaGen provides in vitro testing for the cosmetic, chemical and pharmaceutical industries, which obviates the need for animal testing. The company is listed on Nasdaq First North Growth Market in Stockholm.

Vator Securities acted as financial advisor.

The Baker McKenzie team consisted of Joakim Falkner (Picture), Stefan Balazs, Ian Gulam and Per Blom.

Involved fees earner: Stefan Balazs – Baker McKenzie; Per Blom – Baker McKenzie; Joakim Falkner – Baker McKenzie; Ian Gulam – Baker McKenzie;

Law Firms: Baker McKenzie;

Clients: SenzaGen AB;